8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 7, 2008)

Filed February 7, 2008For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 7, 2008, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2007. This filing is crucial for investors as it provides an update on the company's financial performance and operational status during that period. While the 8-K itself doesn't contain the detailed financial figures, it explicitly references a furnished press release (Exhibit 99.1) which would contain the comprehensive earnings data, operational highlights, and potentially forward-looking statements from the company's management. Investors should pay close attention to the press release for details on revenue, net loss, cash position, and any significant developments in Alnylam's RNA interference (RNAi) therapeutics pipeline. This information is vital for assessing the company's progress, the valuation of its research and development efforts, and its overall financial health as it navigates the competitive biotechnology landscape.

Key Highlights

  • 1Announcement of financial results for the quarter and full year ended December 31, 2007.
  • 2Filing of an 8-K Current Report on February 7, 2008.
  • 3Press Release dated February 7, 2008, furnished as Exhibit 99.1 contains the detailed financial and operational information.
  • 4Information provided pertains to the company's performance as of December 31, 2007.
  • 5The filing serves as a notification of the earnings release rather than containing the full financial statements within the 8-K body.
  • 6Clarification that furnished information is not deemed 'filed' for certain SEC liability purposes unless specifically incorporated by reference.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Alnylam Pharmaceuticals, Inc.'s financial results for the quarter and full year ended December 31, 2007, and to furnish the accompanying press release which contains the detailed financial information.

The detailed financial results and operational updates are provided in the press release dated February 7, 2008, which is furnished as Exhibit 99.1 to this 8-K filing.

Alnylam Pharmaceuticals announced its financial results for the quarter and year ended December 31, 2007, on February 7, 2008, which is the date of this 8-K filing.

No, this 8-K filing does not contain the actual financial statements within its body. It references a press release (Exhibit 99.1) that contains the detailed financial information and results.